DYADIC INTERNATIONAL INC — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Dyadic reported Q2 2026 revenue of $961,138 (down 0.6% YoY) and net loss of $2,123,884 ($0.06 per share). Cash declined 44% from $8.6M (Dec 2025) to $4.8M (June 2026). The company announced initial product shipments across recombinant proteins, partnerships with Proliant Health Biologicals, Fermbox Bio, and Inzymes, and Gates Foundation-funded antibody programs, but management disclosed substantial doubt about going-concern status for 12 months post-June 30, 2026.
Why this rating
Cash burn ($3.8M in 6 months) equals 16% of market cap; going-concern warning is material. Commercialization momentum is real but early-stage revenues immaterial ($961K). Debt of $5M+ versus equity deficit of $2.4M creates solvency pressure. For $24M market-cap company, this trajectory is trajectory-threatening without capital raise.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.